Carmat

Carmat's mission is to develop and commercialize a permanent, fully implantable artificial heart to address the unmet need in end-stage biventricular heart failure. Its key achievement is the Aeson® device, which has obtained CE Mark approval in Europe and is under investigation in a pivotal U.S. study (EFICAS). The company's strategy is to methodically advance clinical validation, secure regulatory approvals in key markets, and establish the infrastructure for commercial rollout, positioning Aeson® as a transformative alternative to heart transplantation.

The Aeson® platform is a fully implantable, bioprosthetic total artificial heart that utilizes biocompatible bovine tissue surfaces to minimize thrombogenicity and features embedded sensors with an auto-regulatory system to physiologically adapt cardiac output to patient activity.

Carmat's primary competition is SynCardia's temporary TAH, an older pneumatic technology. It is not directly comparable to market-dominant LVADs (Abbott, Medtronic), which treat a different patient subset (univentricular failure). Carmat holds a first-mover advantage in advanced, bioprosthetic TAHs over earlier-stage developmental competitors like Bivacor.